@RheumNow So in GCA, we don’t know if therapies can truly disease modify at all. There’s a lot of grumbling disease, and it’s unclear whether we can stop long-term vascular issues. And in PMR, we have very little data on early therapy at all. So what’s the justification? #ACR23 @RheumNow https://t.co/spAMqfSOy2